Creating Better Medicines through Better Conjugation

Published on: 
BioPharm International, BioPharm International-12-16-2013, Volume 2013 eBook, Issue 1

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.

 

Advertisement

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.

from BioPharm International’s 2013 Innovation Updates and Strategies eBook.